TRIAL•IN Pharma // August 13, 2019 .
Stage 4 Cancer .
Don’t miss opportunities to get drugs like this in a clinical trial setting!
Why?
Lurbinectedin Monotherapy as a second-line therapy in patients with small cell lung cancer, SCLC, elicited a 68.6% response to treatment.
The 68.6% response in the phase II study comprised tumor shrinkage occurring in 37 of 105 patients with SCLC where additional 35 patients had stable disease. Furthermore, the median time to worsening of the disease under the treatment was 3.9 months and half of patients lived 9.3 months and longer, which is longer than what we see with other studies.
About the trial
Lurbinectedin has been tested previously in some smaller phase I studies, mostly in combination with other chemotherapies.
*.- This cancer constitutes approx. 15% of lung cancers and is considered to be particularly aggressive.
*.- Its source is in cells from the central region of the lung and connection was found with smoking habits and history.
*.- This cancer spreads rapidly.
Lung cancer develops in the lungs for many years. It is a leading cause in death by cancer in the US, Western countries.
The lungs are a double respiratory organ with a sponge-like texture and shaped like a cone in the chest. The lungs provide the body with oxygen and remove carbon dioxide from the body in the process of breathing.
For most patients with stage 4 metastatic lung cancer, current treatments are insufficiently effective. This gives rise to the need for innovative strategies with greater efficacy in fighting the disease. The National Cancer Institute, NCI, highlights the fact that for a certain group of lung cancer patients, the best treatment option is to join one of the many clinical trials existing worldwide aiming to increase their chances of therapeutic success.